The product is developed by Novartis with support from Camurus for treatment of acromegaly and neuroendocrine tumours and has several important advantages over current marketed products. CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus’ proprietary FluidCrystal® injection depot technology.
CAM2029 comprises the active substance octreotide, which is a synthetic peptide analogue of the endogenous peptide hormon somatostatin. Somatostatin analogues (SSA) are today standard in the safe and effective symptomatic treatment of patients with acromegaly and neuroendocrine tumors (NETs). SSAs have in clinical trials demonstrated efficacy against tumors and is a treatment option for unresectable NETs. Current marketed SSA products include short acting octreotide (Sandostatin® from Novartis and generic versions), the market leading formulation octreotide LAR (Sandostatin® LAR® from Novartis), and two long-acting formulations of lanreotide (Somatuline® LA® and Somatuline® Autogel® from Ipsen).
CAM2029 is provided in a prefilled syringe equipped with a needle stick protection device. The product is conveniently administered subcutaneously , also by the patient itself, without any complicated reconstitution steps or conditioning requirements before use. Moreover, CAM2029 is compatible with autorinjector devices, which may further facilitate patient self-administration.
CAM2029 key properties
- Simple and convenient administration by prefilled syringe
- Thin needle and small injection volume
- Adapted for self-administration
- High bioavailability
- Manufacturing by standard processes